Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.
DNA polymorphisms have been identified in the genes encoding a number of the cytochrome P450 (CYP) enzymes, leading to wide interindividual variation in drug clearance. CYP2D6 metabolizes a significant number of clinically used medications, and genetic variants of the CYP2D6 isozyme that result in varying levels of metabolic activity are of clinical importance in some settings. The exact nature of the clinical effect caused by polymorphisms of the gene depends on the drug in question and the specific variant alleles expressed, as individual variants result in differing phenotypes with a range of levels of enzymatic activity. Compromised drug efficacy due to CYP2D6 variation has been documented with a variety of agents, and this review considers a number of examples, including the 5-HT(3)-receptor antagonists, which are used in oncology supportive care for the prophylaxis of nausea and vomiting. CYP2D6 is involved in the metabolism of all of the most commonly available agents, except granisetron, and their efficacy and side effects may therefore be affected by the CYP2D6 polymorphism. Significant interethnic differences in CYP2D6 allele frequencies have been demonstrated from studies across many countries. However, incidences of polymorphisms in the U.S. population have been challenging to characterize because of the country's wide ethnic diversity. The CYP2D6 polymorphism may become more important as robust clinical tests become widely available and as the use of multiple medications and the attendant risk for drug-drug interactions increases.
Bernard
Stephen
S
Division of Hematology and Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7305, USA. bernmed@med.unc.edu
Neville
Kathleen A
KA
Nguyen
Anne T
AT
Flockhart
David A
DA
D000483:Alleles; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics* / Q000378:metabolism; D005006:Ethnicity / Q000235:genetics*; D006801:Humans; D015994:Incidence; D010597:Pharmacogenetics; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics*; D044406:Receptors, Serotonin, 5-HT3 / Q000235:genetics / Q000378:metabolism; D014481:United States
D000970:Antineoplastic Agents; D044406:Receptors, Serotonin, 5-HT3; D019389:Cytochrome P-450 CYP2D6